Cutaneous T-Cell Lymphoma (CTCL): Mycosis Fungoides, Staging, and Treatment — Overview, Diagnosis & Treatment Options | MyMedicPlus

Cutaneous T-cell lymphoma (CTCL) is a heterogeneous group of primary cutaneous non-Hodgkin lymphomas arising from skin-homing CD4+ (helper) T cells. Mycosis fungoides (MF) is the most common subtype, accounting for approximately 50% of all primary cutaneous lymphomas. Sézary syndrome (SS) — the leukemic variant — is a clinically distinct entity. Other CTCL subtypes include primary cutaneous CD30+ lymphoproliferative disorders (lymphomatoid papulosis and primary cutaneous anaplastic large cell lymphoma [pcALCL]), subcutaneous panniculitis-like T-cell lymphoma, and rare aggressive subtypes. MF follows an indolent course in most patients — particularly those with early patch/plaque stage disease — with a natural history measured in years to decades, and prognosis for early MF is similar to age-matched controls. Advanced MF with skin tumors, systemic involvement, or large cell transformation carries significantly worse prognosis. The pathognomonic histological feature of MF is epidermotropism — preferential infiltration of the epidermis by atypical T lymphocytes — forming Pautrier microabscesses in fully developed lesions.

The etiology of CTCL remains incompletely understood. The malignant T-cell clone in MF originates from mature memory skin-homing CD4+ T cells (Th2-skewed, expressing skin-homing markers CLA, CCR4, CCR10). Chronic antigen stimulation from environmental allergens, industrial chemical exposure, or persistent viral infections has been proposed to initiate clonal T-cell expansion, but no causative antigen has been definitively identified. A role for HTLV-1 has been excluded in most CTCL cases (in contrast to ATLL). Accumulating genomic aberrations — somatic mutations in JAK-STAT pathway genes (PLCG1, STAT5B), TP53, and chromatin remodeling genes — drive progression from early to advanced disease. Clonal T-cell receptor (TCR) rearrangement is a diagnostic hallmark. Risk factors include older age (median diagnosis at ~55 years for MF), male sex (2:1 male predominance), and Black race (higher incidence in African Americans in the US). Occupational exposure to certain chemicals, pesticides, and solvents has been inconsistently associated. Most cases are sporadic.

MF progresses through three characteristic clinical stages. Patch stage: persistent, poorly defined, erythematous (pink-red), slightly scaly patches or thin plaques — often in sun-protected areas (bathing suit distribution: buttocks, inner thighs, axillae, breasts) — that may initially resemble eczema or psoriasis and persist for months to years. Pruritus (itching) may be mild or absent at this stage. Plaque stage: patches progress to well-defined, elevated, indurated, and often darker plaques with more marked pruritus. Poikiloderma (hyperpigmentation, hypopigmentation, telangiectasia, and atrophy) may develop. Tumor stage: raised, dome-shaped, violaceous nodules or tumors with a tendency to ulcerate, reflecting dermal and subcutaneous invasion. Systemic involvement may develop at this stage. Large cell transformation — histological transformation to CD30-positive or negative large cell lymphoma — signals aggressive disease with poor prognosis. Systemic symptoms including fever, night sweats, and weight loss (B symptoms) occur in advanced disease. Peripheral blood involvement (Sézary cells) and lymphadenopathy indicate extracutaneous spread.

Diagnosis requires clinicopathological correlation — no single diagnostic feature is sufficient. Skin biopsy (multiple biopsies from representative lesions, ideally without prior topical corticosteroid treatment) shows a superficial band-like or perivascular infiltrate of lymphocytes with nuclear atypia (cerebriform nuclei), epidermotropism (lymphocytes within the epidermis), and — in well-developed cases — Pautrier microabscesses. Immunohistochemistry typically shows a CD3+CD4+CD8− phenotype with aberrant loss of pan-T-cell antigens (CD7 loss most common). T-cell receptor (TCR) clonality by PCR (BIOMED-2/IdentiClone protocol) detects a dominant T-cell clone in skin and blood. Flow cytometry of peripheral blood characterizes Sézary cell immunophenotype (CD4+CD26− or CD4+CD7−). ISCL/EORTC staging: Stage I–IIA (skin-limited, patch/plaque); Stage IIB (skin tumors); Stage III (erythroderma); Stage IVA (blood or lymph node involvement); Stage IVB (visceral involvement). CT of neck, thorax, abdomen, and pelvis with PET-CT assesses nodal and visceral disease in stages ≥IIB. Lymph node biopsy grades nodal involvement (N1–N4). HTLV-1 serology excludes adult T-cell leukemia/lymphoma. Differential diagnoses include psoriasis, eczema, contact dermatitis, drug eruption, and other lymphomas.

Treatment is stage-adapted per NCCN and EORTC/ISCL consensus guidelines. For early-stage MF (IA–IIA): skin-directed therapy (SDT) is the cornerstone. Phototherapy — narrowband UVB (NB-UVB, preferred for patches) or psoralen + UVA (PUVA, for thicker plaques) — achieves complete responses in 50–90% of patch/plaque stage disease. Topical mechlorethamine 0.016% gel (Valchlor) is FDA-approved for stage I MF and achieves responses in 60–70% of patients. Topical corticosteroids (high-potency) provide symptomatic relief and short-term lesion control. Topical bexarotene and imiquimod are additional options. Localized radiation therapy (8 Gy in 2 fractions) is used for persistent tumors. Total skin electron beam therapy (TSEBT) at 12–36 Gy is used for extensive refractory patch/plaque or tumor-stage MF. For advanced-stage MF (IIB–IVB): systemic therapy is required. Brentuximab vedotin (BV — anti-CD30 antibody-drug conjugate) plus chemotherapy (CHP) is first-line for CD30-expressing CTCL — the ALCANZA trial demonstrated superior response rates versus physician-choice comparators (methotrexate or bexarotene). Single-agent brentuximab vedotin (for CD30+ cases), romidepsin (HDAC inhibitor), vorinostat (HDAC inhibitor), bexarotene (retinoid), interferon-alpha, and methotrexate are sequential options. Mogamulizumab (anti-CCR4) is approved for relapsed/refractory MF and Sézary syndrome. Allogeneic stem cell transplantation (allo-SCT) is considered for eligible patients with relapsed/refractory advanced disease.

The prognosis for cutaneous T-cell lymphoma (CTCL), particularly mycosis fungoides (MF), is strongly determined by disease stage at presentation. Early-stage MF (stage IA — patches limited to less than 10% of body surface area) carries an excellent prognosis — 10-year disease-specific survival exceeds 95%, with life expectancy similar to age-matched controls, and many patients live for decades with chronic, indolent disease managed with skin-directed therapies. Stage IB (patches or plaques over ≥10% BSA) also has a favorable prognosis with 10-year overall survival of approximately 75–80%. The prognosis worsens significantly with tumor-stage disease (stage IIB) — 5-year overall survival falls to 30–50% — particularly when large cell transformation occurs, which carries a median survival under 2 years. Stage III erythrodermic MF without significant blood involvement has a 5-year overall survival of approximately 55–60%. Stage IVA–IVB disease (Sézary syndrome with blood involvement, or visceral disease) has a 5-year overall survival of 20–40%. Key adverse prognostic factors include tumor stage, extent of skin involvement, presence of blood involvement (Sézary cell count), large cell transformation, elevated LDH, and advanced age. Allogeneic stem cell transplantation offers the best chance of durable remission in advanced-stage disease but carries substantial treatment-related mortality. Brentuximab vedotin achieves superior responses compared to physician-choice chemotherapy in CD30-positive cases (ALCANZA trial). Long-term psychosocial support is integral to management given the chronic, relapsing, and disfiguring nature of advanced disease, and ongoing participation in specialist skin lymphoma clinics improves outcomes.

There are no established preventive measures for CTCL. Avoidance of excessive UV exposure is paradoxical in CTCL — UVB and PUVA phototherapy are actually used therapeutically. Patients with early MF on phototherapy should still use regular sunscreen and protective clothing when not undergoing treatment to minimize UV-related skin damage and secondary skin cancer risk. Long-term management of CTCL requires ongoing dermatological surveillance — typically every 3–6 months for early-stage disease and every 1–3 months for advanced or unstable disease. Response assessment uses the modified Severity-Weighted Assessment Tool (mSWAT) for skin burden and ISCL/EORTC criteria for overall response. PUVA-associated secondary skin cancers (squamous cell carcinoma, basal cell carcinoma) require annual full-body skin examinations. Patients on HDAC inhibitors need monitoring for cardiotoxicity (QT prolongation) and myelosuppression. Psychosocial support, patient advocacy organizations (Cutaneous Lymphoma Foundation), and peer support are important aspects of care given the chronic, relapsing, and disfiguring nature of advanced CTCL.

Persistent skin patches, plaques, or itchy rashes that fail to respond to standard topical treatments for eczema or psoriasis within 4–6 weeks — particularly in sun-protected distribution areas (buttocks, inner thighs, axillae, breast folds) — should be evaluated by a dermatologist with biopsy to exclude early CTCL. Patients with a known diagnosis of MF who develop new ulcerated skin nodules or tumors, rapidly spreading skin involvement, lymph node enlargement, generalized redness (erythroderma), unexplained fever, night sweats, or weight loss should seek urgent specialist review for disease progression or large cell transformation. Severe intractable pruritus causing sleep disturbance and quality-of-life impairment requires specialist management. Any skin biopsy showing atypical lymphocytes with epidermotropism should be reviewed at a specialist dermatopathology/lymphoma center experienced in CTCL diagnosis. Referral to a multidisciplinary skin lymphoma clinic combining dermatology, hematology/oncology, and radiation oncology expertise is recommended for all patients beyond stage IA MF.